Observational Study of Long Acting Injectable Medications (LAIs) in Schizophrenia (OASIS)

Inclusion Criteria: * Must be able to speak, read and understand English * Diagnosis of schizophrenia as defined by the treating clinician * Newly initiating treatment with 1 of 4 atypical Long Acting Injectables (LAIs): Abilify Maintena, Aristada, Invega Sustenna, or Risperdal Consta) * Additional criteria may apply Exclusion Criteria: * Currently participating or planning to participate in an interventional clinical study, or has completed participation in an interventional clinical study within 30 days before enrollment * In the opinion of the investigator, is currently an imminent danger to himself/herself. \[Note: A prior history of suicidal ideation or suicidal attempt is not exclusionary.\] * Additional criteria may apply